Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523040 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide for Adult Histiocyte Disorders
A Phase 2 study of Langerhans Cell Histiocytosis (LCH) and Histiocytoses Erdheim-chester Disease, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02523040 is a Phase 2 study of Langerhans Cell Histiocytosis (LCH) and Histiocytoses Erdheim-chester Disease that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02523040, a Phase 2 study of Langerhans Cell Histiocytosis (LCH) and Histiocytoses Erdheim-chester Disease, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).
Conditions Studied
Interventions
- DRUG Lenalidomide
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-08 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02523040
The ClinicalTrials.gov registry entry for NCT02523040 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Langerhans Cell Histiocytosis (LCH) appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.
NCT02523040 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02523040 about?
NCT02523040 is a clinical study titled "Lenalidomide for Adult Histiocyte Disorders". This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).
What is the current status of trial NCT02523040?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-08. Estimated completion is 2026-02.
What conditions does trial NCT02523040 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS).
What interventions are being tested in trial NCT02523040?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02523040?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02523040 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis (LCH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Langerhans Cell Histiocytosis (LCH)
All registered trials for this condition
Histiocytoses Erdheim-chester Disease
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.